Bottom line
Is ERHSX a good fund? The bottom line
ERHSX is a share class of Eaton Vance Worldwide Health Sciences Fund, an actively managed health care sector mutual fund from Morgan Stanley.
Its expense ratio is 1.43% — about $143 a year on every $10,000 invested, more expensive than 79% of health care sector funds we track.
It returned +3.2% over one year, +6.2% a year over five years, +6.7% a year over ten (as of Dec 31, 2024, per its prospectus).
With $758 million in net assets and 42 holdings, its largest position is Eli Lilly & Co (12.5%) and the top 10 make up 58.6% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 63% top-holdings overlap).
What stands out
- 5-year return beat 72% of category peers
- No front-end sales load
What to watch
- Expensive for its category (1.43%)
- Concentrated: top 10 holdings are 58.6% of assets
- 12b-1 marketing fee of 0.5% a year
Updated Nov 19, 2026
What ERHSX invests in
The Funds investment objective is to seek long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies.
The Fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies (health sciences companies) (the 80% Policy). A company will be considered to be a health sciences company if, at the time of investment: (i) the company is classified as a member of the Global Industry Classification Standard (GICS) health care sector; (ii) the company is a component of the S&P 500 Health Care Index or the MSCI World Health Care Index; or (iii) 50% or more of the companys sales, earnings or assets will arise from or will be dedicated to the application of…
From the fund's prospectus (filed Dec 23, 2025).
ERHSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ERHSX | +3.2% | +6.2% | +6.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What ERHSX costs
On a $10,000 investment, ERHSX's 1.43% expense ratio costs about $143 a year. The prospectus estimates $1,744 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
ERHSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 12.47% |
| 2 | AbbVie Inc | 6.46% |
| 3 | Johnson & Johnson | 6.45% |
| 4 | AstraZeneca PLC | 6.24% |
| 5 | UnitedHealth Group Inc | 5.49% |
| 6 | Roche Holding AG | 5.44% |
| 7 | Merck & Co Inc | 5.08% |
| 8 | Bristol-Myers Squibb Co | 4.25% |
| 9 | Vertex Pharmaceuticals Inc | 3.38% |
| 10 | Gilead Sciences Inc | 3.34% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 58.6% of the fund. See all top 25 holdings and asset mix →
Alternatives to ERHSX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 63% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 63% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 62% | Compare |
| iShares | IXJ iShares Global Healthcare ETF | 0.38% | 74% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 63% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 69% | Compare |